The present invention is concerned with isoxazole-pyridazines of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.
本发明涉及式I的异噁唑-吡啶嗪,其具有对GABA A α5受体的亲和力和选择性,其制造,含有它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物可用作认知增强剂或用于治疗和/或预防认知障碍,如阿尔茨海默病。
PYRIDAZINES
申请人:Lucas Matthew C.
公开号:US20100286159A1
公开(公告)日:2010-11-11
The present invention is concerned with isoxazole-pyridazines of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.
本发明涉及式I的异噁唑-吡啶嗪化合物,具有对GABA A α5受体的亲和力和选择性,它们的制造、含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物可用作认知增强剂或用于治疗和/或预防认知障碍,如阿尔茨海默病。